Photobiomodulation therapy in age-related macular degeneration

Purpose of review To review the available data supporting the use of photobiomodulation therapy (PBT) in the treatment of age-related macular degeneration (AMD). Recent findings PBT might be used in treating nonexudative AMD. Limited evidence suggests that exudative AMD may also benefit from PBT. Summary The optimal device would deliver doses of 60 J/cm 2 or more with a multiwavelength composition through the pupil over short treatment intervals. Safe upper limits have not been established. More studies are needed to evaluate the efficacy of PBT in treating exudative and nonexudative AMD.